Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: An open-label, single- and multiple-dose study

Clinical Therapeutics

Volumn 29, Issue 9, 2007, Pages 2082-2092

  James, Laura ^a   Walson, Philip ^b   Lomax, Kathleen ^c   Kao, Richard ^c   Varughese, Shanti ^c   Reyes, Josephine ^c  

^a ARKANSAS CHILDREN S HOSPITAL   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c EISAI INC   (United States)

Author keywords

erosive esophagitis; gastroesophageal reflux disease; lansoprazole; omeprazole; rabeprazole

Indexed keywords

RABEPRAZOLE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACCUMULATION; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; DYSMENORRHEA; EOSINOPHIL COUNT; FATIGUE; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUTROPHIL COUNT; PATIENT COMPLIANCE; PERIORBITAL EDEMA; POTASSIUM BLOOD LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SCHOOL CHILD; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; TIME TO MAXIMUM PLASMA CONCENTRATION; URINE VOLUME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ANALYSIS OF VARIANCE; ANTI-ULCER AGENTS; AREA UNDER CURVE; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; PROTON PUMP INHIBITORS; TABLETS;

EID: 36749054044     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.09.007     Document Type: Article

References (27)

1. Cezard J. Managing gastro-oesophageal reflux disease in children. Digestion 69 Suppl 1 (2004) 3-8
2. Nelson S., Chen E., Syniar G., Christoffel K., and for the Pediatric Practice Research Group. Prevalence of symptoms of gastroesophageal reflux during infancy. A pediatric practice-based survey. Arch Pediatr Adolesc Med 151 (1997) 569-572
3. Nelson S., Chen E., Syniar G., Christoffel K., and for the Pediatric Practice Research Group. Prevalence of symptoms of gastroesophageal reflux during childhood: A pediatric practice-based survey. Arch Pediatr Adolesc Med 154 (2000) 150-154
4. Treem W., Davis P., and Hyams J. Gastroesophageal reflux in the older child: Presentation, response to treatment and long-term follow-up. Clin Pediatr (Phila) 30 (1991) 435-440
5. Shepherd R., Wren J., Evans S., et al. Gastroesophageal reflux in children. Clinical profile, course and outcome with active therapy in 126 cases. Clin Pediatr (Phila) 26 (1987) 55-60
6. El-Serag H., Gilger M., Kuebeler M., and Rabeneck L. Extraesophageal associations of gastroesophageal reflux disease in children without neurologic defects. Gastroenterology 121 (2001) 1294-1299
7. Dekkers C., Beker J., Thjodleifsson B., et al., for the European Rabeprazole Study Group. Double-blind comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. [published correction appears in Aliment Pharmacol Ther. 1999;13:567]. Aliment Pharmacol Ther 13 (1999) 49-57
8. Thjodleifsson B., Rindi G., Fiocca R., et al., for the European Rabeprazole Study Group. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment Pharmacol Ther 17 (2003) 343-351
9. Miner Jr. P., Orr W., Filippone J., et al. Rabeprazole in nonerosive gastroesophageal reflux disease: A randomized placebo-controlled trial. Am J Gastroenterol 97 (2002) 1332-1339
10. Gibbons T., and Gold B. The use of proton pump inhibitors in children: A comprehensive review. Paediatr Drugs 5 (2003) 25-40
11. AcipHex (rabeprazole) (2003), Eisai Medical Research Inc, Ridgefield Park, NJ [package insert]
12. Yasuda S., Ohnishi A., Ogawa T., et al. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther 32 (1994) 466-473
13. Kearns G., and Winter H. Proton pump inhibitors in pediatrics: Relevant pharmacokinetics and pharmacodynamics. J Pediatr Gastroenterol Nutr 37 Suppl 1 (2003) S52-S59
14. Andersson T., Hassall E., Lundborg P., et al., for the International Pediatric Omeprazole Pharmacokinetic Group. Pharmacokinetics of orally administered omeprazole in children. Am J Gastroenterol 95 (2000) 3101-3106
15. Hassall E., Israel D., Shepherd R., et al., for the International Pediatric Omeprazole Study Group. Omeprazole for treatment of chronic erosive esphagitis in children: A multicenter study of efficacy, safety, tolerability and dose requirements. J Pediatr 137 (2000) 800-807
16. Declaration of Helsinki. Ethical principles for biomedical research involving human subjects
17. Available at:. http://www.wma.net/e/policy/b3.htm Accessed August 17, 2007
18. 21 CFR, parts 50, 54, and 56
19. Available at:. http://www.access.gpo.gov/nara/cfr/waisidx_01/21cfrv1_01.html Accessed August 17, 2007
20. Guideline for industry. Structure and content of clinical study reports
21. Available at:. http://www.fda.gov/cder/guidance/iche3.pdf Accessed August 17, 2007
22. Swan S., Hoyumpa A., and Merritt G. Review article: The pharmacokinetics of rabeprazole in health and disease. Aliment Pharmacol Ther 13 Suppl 3 (1999) 11-17
23. Horn J. Review article: Relationship between the metabolism and efficacy of proton pump inhibitors-focus on rabepra7ole. Aliment Pharmacol Ther 20 Suppl 6 (2004) 11-19
24. Furuta T., Ohashi K., Kosuge K., et al. CYP2C19 genotype status and eFFect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65 (1999) 552-561
25. Sakai T., Aoyama N., Kita T., et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 18 (2001) 721-727
26. Yasuda S., Horai Y., Tomono Y., et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status. Clin Pharmacol Ther 58 (1995) 143-154
27. Horai Y., Kimura M., Furuie H., et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther 15 (2001) 793-803